Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker DNLI
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Peter Scott Chin Chief Medical Officer | DNLI Denali Therapeutics Inc. | Sale | 1,654 | $22.29 | $36.9K Sale | Form 4 ↗ |
| Sep 2, 2026 | Nancy Thornberry Director | DNLI Denali Therapeutics Inc. | Sale | 615 | $23.74 | $14.6K Sale | Form 4 ↗ |
| Sep 2, 2026 | Nancy Thornberry Director | DNLI Denali Therapeutics Inc. | Sale | 10,824 | $22.85 | $247.3K Sale | Form 4 ↗ |
| Sep 1, 2026 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 2,768 | $23.44 | $64.9K Sale | Form 4 ↗ |
| Aug 11, 2026 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 2,857 | $25.07 | $71.6K Sale | Form 4 ↗ |
| Jan 6, 2026 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 17,218 | $16.50 | $284.1K Sale | Form 4 ↗ |
| Jan 6, 2026 | Ryan J. Watts President and CEO, Director | DNLI Denali Therapeutics Inc. | Sale | 35,198 | $16.50 | $580.8K Sale | Form 4 ↗ |
| Aug 13, 2025 | Carole Ho Chief Medical Officer | DNLI Denali Therapeutics Inc. | Sale | 806 | $14.64 | $11.8K Sale | Form 4 ↗ |
| Aug 12, 2025 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 2,937 | $13.58 | $39.9K Sale | Form 4 ↗ |
| Aug 12, 2025 | Carole Ho Chief Medical Officer | DNLI Denali Therapeutics Inc. | Sale | 2,937 | $13.58 | $39.9K Sale | Form 4 ↗ |
| Jul 9, 2025 | Ryan J. Watts President and CEO, Director | DNLI Denali Therapeutics Inc. | Sale | 495,282 | $15.00 | $7.4M Sale | Form 4 ↗ |
| Jan 7, 2025 | Carole Ho Chief Medical Officer | DNLI Denali Therapeutics Inc. | Sale | 2,907 | $20.81 | $60.5K Sale | Form 4 ↗ |
| Jan 7, 2025 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 2,907 | $20.81 | $60.5K Sale | Form 4 ↗ |
| Jan 7, 2025 | Ryan J. Watts President and CEO, Director | DNLI Denali Therapeutics Inc. | Sale | 7,650 | $20.81 | $159.2K Sale | Form 4 ↗ |
| Jan 7, 2025 | Steve E. Krognes Director | DNLI Denali Therapeutics Inc. | Sale | 3,339 | $20.81 | $69.5K Sale | Form 4 ↗ |
| Jan 6, 2025 | Carole Ho Chief Medical Officer | DNLI Denali Therapeutics Inc. | Sale | 12,255 | $20.22 | $247.8K Sale | Form 4 ↗ |
| Jan 6, 2025 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 12,255 | $20.22 | $247.8K Sale | Form 4 ↗ |
| Jan 6, 2025 | Ryan J. Watts President and CEO, Director | DNLI Denali Therapeutics Inc. | Sale | 29,266 | $20.22 | $591.8K Sale | Form 4 ↗ |
| Jan 2, 2025 | Vicki L. Sato Director | DNLI Denali Therapeutics Inc. | Sale | 3,080 | $20.91 | $64.4K Sale | Form 4 ↗ |
| Dec 31, 2024 | Steve E. Krognes Director | DNLI Denali Therapeutics Inc. | Sale | 30,000 | $20.25 | $607.5K Sale | Form 4 ↗ |
| Nov 11, 2024 | David P. Schenkein Director | DNLI Denali Therapeutics Inc. | Sale | 32,312 | $32.87 | $1.1M Sale | Form 4 ↗ |
| Nov 11, 2024 | David P. Schenkein Director | DNLI Denali Therapeutics Inc. | Sale | 27,129 | $32.09 | $870.6K Sale | Form 4 ↗ |
| Nov 7, 2024 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 300 | $31.29 | $9,387 Sale | Form 4 ↗ |
| Nov 7, 2024 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 2,925 | $30.72 | $89.9K Sale | Form 4 ↗ |
| Nov 7, 2024 | Alexander O. Schuth COFO and Secretary | DNLI Denali Therapeutics Inc. | Sale | 12,333 | $29.68 | $366.0K Sale | Form 4 ↗ |
| Nov 7, 2024 | Vicki L. Sato Director | DNLI Denali Therapeutics Inc. | Sale | 1,020 | $30.00 | $30.6K Sale | Form 4 ↗ |
| Nov 1, 2024 | Vicki L. Sato Director | DNLI Denali Therapeutics Inc. | Sale | 3,080 | $27.07 | $83.4K Sale | Form 4 ↗ |
| Oct 18, 2024 | Ryan J. Watts President and CEO, Director | DNLI Denali Therapeutics Inc. | Sale | 40,000 | $27.69 | $1.1M Sale | Form 4 ↗ |
| Sep 30, 2024 | Steve E. Krognes Director | DNLI Denali Therapeutics Inc. | Sale | 30,000 | $29.03 | $870.9K Sale | Form 4 ↗ |
29 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:35 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances